Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Self-reported side effects of the Oxford AstraZeneca COVID-19 vaccine among healthcare workers in Ethiopia, Africa: A cross-sectional study

EA. Yesuf, A. Riad, A. Sofi-Mahmudi, M. Sudhakar, A. Mekonnen, S. Endalkachew, F. Mama, S. Muhidin, B. Ayele, M. Yahya, A. Usman, J. Abafita, M. Klugar

. 2022 ; 10 (-) : 937794. [pub] 20220719

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22025190

Introduction: Ethiopia is the second most populous country in Africa. Ethiopia received most of its COVID-19 vaccines through donations. The Oxford AstraZeneca vaccine is the first to be donated to Ethiopia by the COVAX facility. Healthcare workers were the priority population that received the Oxford AstraZeneca COVID-19 vaccine. However, there was no nationwide study on the safety of the vaccine in Ethiopia. This study aimed to measure the prevalence and predictors of self-reported side effects of the Oxford AstraZeneca vaccine. Materials and methods: The study employed a cross-sectional design. A sample of healthcare workers who took Oxford AstraZeneca COVID-19 vaccine was drawn from four regions of Ethiopia; namely, Amhara, Oromia, Somali, and Southwest. Data were collected on sociodemographic characteristics, medical anamnesis, COVID-19 related anamnesis, and COVID-19 vaccine anamnesis via telephone interview. Descriptive and inferential analyses were done. The software, IBM SPSS Statistics v21.0, was used for analyses of data. Results: Out of 384 people, 346 responded (response rate: 90.1%). Female accounted for 34.1% of the respondents. The mean age of the respondents was 31.0 years (Standard Deviation (SD) = 7.4). Nurses accounted for 43.7% of the respondents. The prevalence of at least one local- and systemic-side effect was 50.6 and 44.5%, respectively. The most frequent local- and systemic- side effect were injection site pain and headache, respectively. Both types of side effects mostly subsided in the first 3 days. A third of healthcare workers with side effects took at least one medication. Paracetamol followed by diclofenac sodium were taken by healthcare workers to overcome side effects. There was no independent predictor of local side effect. After controlling for age and chronic diseases, the odds of healthcare workers with COVID-19 like symptoms to experience systemic side effects was 1.38 (Confidence Interval (CI): 1.04-1.82) times more than that of healthcare workers without COVID-19 like symptoms. Conclusions: The prevalence of local- and systemic-side effects of the Oxford AstraZeneca COVID-19 vaccine was modest. As the symptoms were mostly common in the first 3 days, it is preferable to monitor healthcare workers at least in the first 3 days following the administration of the vaccine.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22025190
003      
CZ-PrNML
005      
20221031100532.0
007      
ta
008      
221017s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fpubh.2022.937794 $2 doi
035    __
$a (PubMed)35928493
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Yesuf, Elias Ali $u Department of Health Policy and Management, Jimma University, Jimma, Ethiopia
245    10
$a Self-reported side effects of the Oxford AstraZeneca COVID-19 vaccine among healthcare workers in Ethiopia, Africa: A cross-sectional study / $c EA. Yesuf, A. Riad, A. Sofi-Mahmudi, M. Sudhakar, A. Mekonnen, S. Endalkachew, F. Mama, S. Muhidin, B. Ayele, M. Yahya, A. Usman, J. Abafita, M. Klugar
520    9_
$a Introduction: Ethiopia is the second most populous country in Africa. Ethiopia received most of its COVID-19 vaccines through donations. The Oxford AstraZeneca vaccine is the first to be donated to Ethiopia by the COVAX facility. Healthcare workers were the priority population that received the Oxford AstraZeneca COVID-19 vaccine. However, there was no nationwide study on the safety of the vaccine in Ethiopia. This study aimed to measure the prevalence and predictors of self-reported side effects of the Oxford AstraZeneca vaccine. Materials and methods: The study employed a cross-sectional design. A sample of healthcare workers who took Oxford AstraZeneca COVID-19 vaccine was drawn from four regions of Ethiopia; namely, Amhara, Oromia, Somali, and Southwest. Data were collected on sociodemographic characteristics, medical anamnesis, COVID-19 related anamnesis, and COVID-19 vaccine anamnesis via telephone interview. Descriptive and inferential analyses were done. The software, IBM SPSS Statistics v21.0, was used for analyses of data. Results: Out of 384 people, 346 responded (response rate: 90.1%). Female accounted for 34.1% of the respondents. The mean age of the respondents was 31.0 years (Standard Deviation (SD) = 7.4). Nurses accounted for 43.7% of the respondents. The prevalence of at least one local- and systemic-side effect was 50.6 and 44.5%, respectively. The most frequent local- and systemic- side effect were injection site pain and headache, respectively. Both types of side effects mostly subsided in the first 3 days. A third of healthcare workers with side effects took at least one medication. Paracetamol followed by diclofenac sodium were taken by healthcare workers to overcome side effects. There was no independent predictor of local side effect. After controlling for age and chronic diseases, the odds of healthcare workers with COVID-19 like symptoms to experience systemic side effects was 1.38 (Confidence Interval (CI): 1.04-1.82) times more than that of healthcare workers without COVID-19 like symptoms. Conclusions: The prevalence of local- and systemic-side effects of the Oxford AstraZeneca COVID-19 vaccine was modest. As the symptoms were mostly common in the first 3 days, it is preferable to monitor healthcare workers at least in the first 3 days following the administration of the vaccine.
650    _2
$a dospělí $7 D000328
650    12
$a COVID-19 $x prevence a kontrola $7 D000086382
650    12
$a ChAdOx1 nCoV-19 $x škodlivé účinky $7 D000090985
650    _2
$a průřezové studie $7 D003430
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a zdravotnický personál $7 D006282
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a zpráva o sobě $7 D057566
650    _2
$a průzkumy a dotazníky $7 D011795
651    _2
$a Etiopie $x epidemiologie $7 D005002
655    _2
$a časopisecké články $7 D016428
700    1_
$a Riad, Abanoub $u Department of Public Health, Masaryk University, Brno, Czechia $u Czech National Center for Evidence-Based Healthcare and Knowledge Translation (Cochrane Czech Republic, Czech EBHC: JBI Center of Excellence, Masaryk University GRADE Center), Institute of Biostatistics and Analyses, Masaryk University, Brno, Czechia
700    1_
$a Sofi-Mahmudi, Ahmad $u Cochrane Iran Associate Center, National Institute for Medical Research Development, Tehran, Iran $u Seqiz Health Network, Kurdistan University of Medical Sciences, Seqiz, Iran
700    1_
$a Sudhakar, Morankar $u Department of Health, Behavior and Society, Jimma University, Jimma, Ethiopia
700    1_
$a Mekonnen, Addisalem $u Jimma University Medical Center, Jimma University, Jimma, Ethiopia
700    1_
$a Endalkachew, Selamawit $u Department of Pediatrics and Child Health, Jimma University, Jimma, Ethiopia
700    1_
$a Mama, Feyissa $u Jimma University Medical Center, Jimma University, Jimma, Ethiopia
700    1_
$a Muhidin, Semira $u Department of Public Health, Woldia University, Woldia, Ethiopia
700    1_
$a Ayele, Bethelhem $u Gebretsadik Shawo Hospital, Southwest Health Bureau, Bonga, Ethiopia
700    1_
$a Yahya, Mohammed $u Jigjiga University Specialized Hospital, Jigjiga University, Jigjiga, Ethiopia
700    1_
$a Usman, Abduselam $u Department of Gynecology and Obstetrics, Jigjiga University, Jigjiga, Ethiopia
700    1_
$a Abafita, Jemal $u Department of Economics, Jimma University, Jimma, Ethiopia
700    1_
$a Klugar, Miloslav $u Czech National Center for Evidence-Based Healthcare and Knowledge Translation (Cochrane Czech Republic, Czech EBHC: JBI Center of Excellence, Masaryk University GRADE Center), Institute of Biostatistics and Analyses, Masaryk University, Brno, Czechia $u Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia
773    0_
$w MED00186211 $t Frontiers in public health $x 2296-2565 $g Roč. 10, č. - (2022), s. 937794
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35928493 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100529 $b ABA008
999    __
$a ok $b bmc $g 1854744 $s 1176480
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 10 $c - $d 937794 $e 20220719 $i 2296-2565 $m Frontiers in public health $n Front Public Health $x MED00186211
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Možnosti archivace